LALBA: A Key Enzyme in The Lactose Synthesis Pathway (G3906)

Target Name: LALBA

NCBI ID: G3906

LALBA

LALBA: A Key Enzyme in The Lactose Synthesis Pathway

LALBA (Lactose synthase B protein) is a protein that is expressed in various tissues and cells in the human body. It is a key enzyme in the lactose biosynthesis pathway, which is the process by which the body produces milk from lactose. LALBA is involved in the catalytic center of the enzyme lactose synthase, which is responsible for catalyzing the conversion of glucose and galactose to lactose.

The lactose synthase pathway is a critical pathway for the production of milk, which is an essential nutrient for the growth and development of infants. Galactose, which is the final step in the lactose biosynthesis pathway, is the main sugar found in milk and is the source of nutrition for most of the world's population. However, galactose is also the source of many of the symptoms associated with lactose intolerance, such as abdominal pain, bloating, and diarrhea.

LALBA is a key enzyme in the lactose synthase pathway that helps to regulate the rate at which galactose is produced. It is known to have a high degree of sequence identity with the protein from the milk biotenurellin gene, which is a gene that encodes the enzyme lactase. This suggests that LALBA and lactase may have similar functions in the lactose biosynthesis pathway.

In addition to its role in lactose biosynthesis, LALBA is also involved in the regulation of cellular processes that are important for cell survival and growth. It is known to be involved in the regulation of cell adhesion, which is the process by which cells stick together to form tissues and organs. LALBA is also involved in the regulation of cell signaling, which is the process by which cells communicate with each other to coordinate their activities.

Given its involvement in the lactose synthase pathway and its potential role in cell signaling, LALBA is a promising drug target for researchers who are interested in developing new treatments for lactose intolerance and other related diseases. Studies have suggested that inhibiting LALBA activity may be an effective way to treat lactose intolerance by reducing the amount of galactose produced in the body.

In addition to its potential as a drug target, LALBA is also a potential biomarker for lactose intolerance. The lactose synthase pathway is a critical pathway for the production of milk, and changes in the rate at which galactose is produced can be an indication of lactose intolerance. For this reason, measuring the level of LALBA activity in the body may be an effective way to diagnose lactose intolerance.

Overall, LALBA is a protein that is involved in the lactose biosynthesis pathway and is potential drug and biomarker target. Further research is needed to fully understand its role in these processes and to develop new treatments for lactose intolerance and other related diseases.

Protein Name: Lactalbumin Alpha

Functions: Regulatory subunit of lactose synthase, changes the substrate specificity of galactosyltransferase in the mammary gland making glucose a good acceptor substrate for this enzyme. This enables LS to synthesize lactose, the major carbohydrate component of milk. In other tissues, galactosyltransferase transfers galactose onto the N-acetylglucosamine of the oligosaccharide chains in glycoproteins

The "LALBA Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LALBA comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets